BF∗F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus

Página do item simplificado
dc.contributor.authorPicceli V.F.
dc.contributor.authorSkare T.L.
dc.contributor.authorNisihara R.M.
dc.contributor.authorNass F.R.
dc.contributor.authorMessias-Reason I.T.
dc.contributor.authorDa Rosa Utiyama S.R.
dc.date.accessioned2024-03-13T00:53:33Z
dc.date.available2024-03-13T00:53:33Z
dc.date.issued2016
dc.description.abstract© The Author(s) 2015.Background: B factor (BF) from the alternative complement pathway seems to participate in the pathophysiology of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Objective: To study the allotypic variability of BF in SLE and their associations with clinical and autoantibodies profile. Methods: BF allotypes were determined by high-voltage agarose gel electrophoresis, under constant cooling, followed by immunofixation with anti-human BF antibody, in 188 SLE patients and 103 controls. Clinical and serological data were obtained from medical examination and records. Results: No significant differences of BF variants between patients and controls were found, neither in relation to epidemiologic or clinical manifestations. Associations of phenotype BF SS07 and allotype BF∗S07 were found with anticardiolipin IgM (aCl-IgM) antibodies (p = 0.014 and p = 0.009 respectively), but not with aCl-IgG, lupus anticoagulant (LA), anti β2GPI or clinical APS. A significant decrease in BF∗F allotype (p = 0.043) and BF SF phenotype (p = 0.018) was detected in patients with anti-phospholipid antibodies as a whole (aCl-IgG, aCl-IgM, LA and anti β2GPI). Conclusions: There is a link between phenotype BF SS07 and allotype BF∗S07 with aCl-IgM in SLE patients; BF∗F allotype could be considered a marker of protection against the development of antiphospholipid antibodies in these patients.
dc.description.firstpage412
dc.description.issuenumber4
dc.description.lastpage417
dc.description.volume25
dc.identifier.doi10.1177/0961203315615222
dc.identifier.issn1477-0962
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/35991
dc.relation.ispartofLupus
dc.rightsAcesso Restrito
dc.subject.otherlanguageAnticardiolipin antibodies
dc.subject.otherlanguageantiphospholipid syndrome
dc.subject.otherlanguagelupus anticoagulant
dc.subject.otherlanguagesystemic lupus erythematosus
dc.titleBF∗F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus
dc.typeArtigo
local.scopus.citations3
local.scopus.eid2-s2.0-84960463290
local.scopus.subjectAdolescent
local.scopus.subjectAdult
local.scopus.subjectAged
local.scopus.subjectAntibodies, Anticardiolipin
local.scopus.subjectAntibodies, Antiphospholipid
local.scopus.subjectAntiphospholipid Syndrome
local.scopus.subjectBiomarkers
local.scopus.subjectCase-Control Studies
local.scopus.subjectComplement Factor B
local.scopus.subjectComplement Pathway, Alternative
local.scopus.subjectElectrophoresis, Agar Gel
local.scopus.subjectFemale
local.scopus.subjectGene Frequency
local.scopus.subjectHumans
local.scopus.subjectImmunoglobulin M
local.scopus.subjectLupus Erythematosus, Systemic
local.scopus.subjectMale
local.scopus.subjectMiddle Aged
local.scopus.subjectPhenotype
local.scopus.subjectPolymorphism, Genetic
local.scopus.subjectPredictive Value of Tests
local.scopus.subjectProtective Factors
local.scopus.subjectRisk Factors
local.scopus.subjectYoung Adult
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84960463290&origin=inward
Arquivos
Coleções
Artigos de periódico